Allotment of 1,50,000 shares on conversion of warrants; acquirer's post-allotment holding is 5.18%
Aarey Drugs & Pharmaceuticals Ltd: Nimit Rajesh Ghatalia has disclosed allotment of 1,50,000 equity shares to him on conversion of warrants.
- Shares Allotted on Warrant Conversion
- 1,50,000 equity shares
- Allotment Date / Board Meeting
- Board Meeting held on 30-09-2026
- Holding Before
- 1500000 shares (4.88%)
- Holding After
- 16,50,000 shares (5.18%)
- Total Voting Capital After
- rises from 30724303 to 31874303 equity shares
Part B of the disclosure records Nimit Rajesh Ghatalia as the acquirer and states that he belongs to the Promoter/Promoter Group of Aarey Drugs & Pharmaceuticals Ltd.
What was disclosed
- 1,50,000 equity shares were allotted to the acquirer on conversion of warrants.
- The allotment was made in the Board Meeting held on 30-09-2026.
- The mode of acquisition is recorded as "ALLOTMENT PURSUANT TO CONVERSION OF WARRANTS".
- The intimation is made under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Holding before and after
- Before the acquisition: 1500000 shares carrying voting rights, being 4.88% of total voting capital, plus warrants entitling the acquirer to 150000 shares, being 0.49% of total voting capital.
- Shares acquired: 1,50,000, being 0.47% of total voting capital.
- After the acquisition: 16,50,000 shares carrying voting rights, being 5.18% of total voting capital and 4.94% of the total diluted voting capital.
Encumbrance
The disclosure records Nil shares in the nature of encumbrance before the acquisition and Nil after it.
Capital of the company
- Total voting capital before the acquisition: 30724303 equity shares.
- Total voting capital after the acquisition: 31874303 equity shares.
- Total diluted share/voting capital after the acquisition: 33354303 equity shares.
How a retail investor may read it
The shares were issued on conversion of warrants that the acquirer already held, so the company's equity base widens from 30724303 equity shares to 31874303 equity shares. When the number of shares goes up, each existing share represents a smaller proportion of the company, other things being equal. Alongside this, the disclosed holding of the acquirer rises from 4.88% to 5.18%, with the post-acquisition figure on a diluted basis stated at 4.94%.
Also from Aarey Drugs & Pharmaceuticals
Revised outcome: Board approves allotment of 11,50,000 equity shares on warrant conversion
7 Oct 2026
Aarey Drugs & Pharmaceuticals Ltd promoter buys 7.71% stake
5 Oct 2026
Aarey Drugs & Pharmaceuticals Ltd shareholder buys 0.47% stake, holding rises to 5.18%
5 Oct 2026
More numbers
- Equity shares allotted on conversion of warrants1,50,000
- Acquirer's post-allotment holding16,50,000
- Acquirer's post-allotment holding as % of capital5.18%
- Shares carrying voting rights held before the acquisition1500000
- Holding before the acquisition as % of total voting capital4.88%
- Warrants held before the acquisition150000
- Warrants before the acquisition as % of total voting capital0.49%
- Shares acquired as % of total voting capital0.47%
- Total voting capital of the company before the acquisition30724303
- Total voting capital of the company after the acquisition31874303
- Total diluted share/voting capital after the acquisition33354303
- Post-acquisition holding as % of total diluted voting capital4.94%
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.